Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jun 20;3(4):e000404.
doi: 10.1136/esmoopen-2018-000404. eCollection 2018.

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?

Marco C Merlano  1 , Ornella Garrone  1
Affiliations
Editorial

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?

Marco C Merlano et al. ESMO Open. .
No abstract available

Keywords: head and neck cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Vermorken JB, Mesia R, Rivera F, et al. . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27. 10.1056/NEJMoa0802656 - DOI - PubMed
    1. Bonner JA, Harari PM, Giralt J, et al. . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78. 10.1056/NEJMoa053422 - DOI - PubMed
    1. Hansel TT, Kropshofer H, Singer T, et al. . The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325–38. 10.1038/nrd3003 - DOI - PubMed
    1. Zuidgest MGP, Goetz I, Groenwold RHH, et al. . Series: pragmatic trials and real world evidence. J Clin Epidemiol 2017;88:7–13. - PubMed
    1. Coloma P V, Bravo P, Lezghed N, et al. . High incidence of cetuximab-related infusion reactions in head and neck patients. ESMO open 2018. - PMC - PubMed

Publication types

LinkOut - more resources